Keyphrases
Advanced Stage
20%
Adverse Effects
20%
Adverse Events
20%
Adverse Events Profile
20%
Anti-cytotoxic
100%
Anti-programmed death-1 Monoclonal Antibody
100%
Checkpoint Inhibitors
20%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
100%
Diarrhea
20%
Endocrine System
20%
Gastrointestinal Tract
20%
General Guidelines
20%
Guideline-based
20%
Immune Checkpoint
20%
Immune System
20%
Immune-related Adverse Events
20%
Liver
20%
Mechanism of Action
40%
Melanoma
20%
Metastatic Melanoma
20%
Monoclonal Antibody
20%
Monotherapy
20%
Nausea
20%
Novel Immunotherapy
20%
Patient Management
20%
PD-1 Inhibitor
20%
Programmed Death-ligand 1 (PD-L1)
60%
Promising Treatment
20%
Pruritus
20%
Rash
20%
Safety Profile
100%
Thyroid Disorders
20%
Treatment Strategy
20%
US FDA
20%
Medicine and Dentistry
Adverse Event
60%
CTLA-4
100%
Diarrhea
20%
Endocrine System
20%
Exanthem
20%
Gastrointestinal Tract
20%
Immune System
20%
Immune-Related Adverse Events
20%
Immunity
20%
Immunotherapy
20%
Malignant Neoplasm
20%
Melanoma
20%
Metastatic Melanoma
20%
Monoclonal Antibody
20%
Monotherapy
20%
Nausea
20%
Programmed Cell Death
100%
Pruritus
20%
Thyroid Disease
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
80%
Cytotoxic T Lymphocyte Antigen 4
100%
Diarrhea
20%
Immunotherapy
20%
Malignant Neoplasm
20%
Melanoma
20%
Metastatic Melanoma
20%
Monoclonal Antibody
20%
Monotherapy
20%
Nausea
20%
Programmed Cell Death
100%
Pruritus
20%
Rash
20%
Thyroid Disease
20%